OVARIAN CANCER and US: fleming

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label fleming. Show all posts
Showing posts with label fleming. Show all posts

Wednesday, July 14, 2010

Gyn Clinical Spotlights | slides/interviews: Dr's Fleming, Monk, Birrer



7 JUNE 2010

These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release:

#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study

The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States

The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States.

View the Primary Expert Analysis with Gini Fleming, MD, and Bradley Monk, MD, and access downloadable slides

View the Supplemental Perspectives and Discussion with Bradley Monk, MD, and Michael Birrer, MD, PhD, and access downloadable slides


Monday, June 07, 2010

Gyn Clinical Spotlights | prIME Oncology



7 JUNE 2010


These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release:

#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study

The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States

The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States.

View the expert analysis with Gini Fleming, MD, and Bradley Monk, MD
View the expert analysis with Bradley Monk, MD, and Michael Birrer, MD, PhD
View eNewsflash